Piramal Pharma stock score and checklist

Piramal Pharma (PPLPHARMA) ranked on quality, valuation and momentum against 1,356 NSE stocks, with an 18-point checklist. Prices as of 18 Nov 2026; results to the quarter ended Sep 2026.

· data for the trading session of Wed 18 Nov 2026

Quality
22 / 100
Weak
From 6 of 6 components
Valuation
n/a
n/a
Loss over the last four quarters: P/E-based valuation does not apply
Momentum
89 / 100
Strong
From 4 of 5 components

Weak quality · Valuation n/a · Strong momentum. Passes 9 of 15 applicable checks.

How each score is made

Every number is ranked against the same number for the other 1,355 scored stocks. The percentile is the share of them it beats (0–100); a score is the average percentile of the components the stock has.

Quality: 22 (Weak)

Profitability, balance sheet strength and steady growth.

ComponentPiramal PharmaPercentile
Return on equity (ROE)Profit over the last four quarters ÷ average shareholders’ equity. Higher ranks higher.-2.6%4
Return on capital employed (ROCE)Pre-tax profit + interest ÷ equity + borrowings. Higher ranks higher.2.3%6
Debt / equityBorrowings ÷ equity (lease liabilities are not in NSE filings, so not counted). Lower ranks higher.0.7015
Interest coverPre-tax profit + interest ÷ interest, last four quarters. Higher ranks higher.0.9×5
Profit growth consistencyShare of the last 8 quarters with profit above the same quarter a year earlier.4 of 8 quarters28
Free cash flow margin FY26Operating cash flow − capex, as a % of the year’s sales. Higher ranks higher.8.6%72

Valuation: n/a

Piramal Pharma made a loss over the last four quarters, so P/E has no meaning and the valuation score is n/a. A score on book value alone would mislead.

Momentum: 89 (Strong)

How the share price has been trending, against other stocks and NIFTY 50.

ComponentPiramal PharmaPercentile
RS rating12-month return with the latest quarter counted twice, ranked against all NSE stocks we track.80 / 9980
vs 200-day averageHow far the price is above (+) or below (−) its 200-day average.+31.2%92
vs 50-day averageHow far the price is above (+) or below (−) its 50-day average.+11.0%91
Place in 52-week range0% = at the 52-week low, 100% = at the 52-week high.88% of the way up92
6-month strength vs NIFTY 50Six-month return minus NIFTY 50’s six-month return.–n/a

18-point checklist

Simple yes/no tests on growth, returns, debt, valuation, trend, holdings and trading. A check is n/a when it doesn’t apply or the data isn’t there; it then doesn’t count either way.

Passes 9 of 15 applicable checks (3 n/a)
#CheckPiramal PharmaResult
1Profit up on a year ago (latest quarter)Rising profit is the main thing that lifts a share’s value over time.₹6 Cr vs −₹99 CrPass
2Sales up on a year ago (latest quarter)Profit growth lasts longer when it comes with more business, not just cost cuts.+28%Pass
3Profit up year on year in at least 6 of the last 8 quartersSteady growth is easier to rely on than one good quarter.4 of 8Fail
4Return on equity (ROE) of 15% or moreHow much profit the company earns on shareholders’ money.-2.6%Fail
5Return on capital employed (ROCE) of 15% or moreProfit on all the capital in the business, borrowed money included.2.3%Fail
6Debt below half of equity (D/E under 0.5)Low debt leaves room to get through a bad year.0.70Fail
7Interest cover of 3× or moreOperating profit should cover interest costs comfortably.0.9×Fail
8Positive free cash flow (latest full year)Cash left after investment is what pays dividends and debt.₹763 Cr (FY26)Pass
9P/E below its sector medianA lower P/E than similar companies means you pay less for each rupee of profit.loss-makingn/a
10P/E below its own 5-year medianCompares today’s price tag with what the market usually paid for this stock.loss-makingn/a
11Price above its 200-day averageThe long-term trend: above the line means the price has been rising over the past ten months.+31.2%Pass
12Price above its 50-day averageThe medium-term trend over about ten weeks.+11.0%Pass
13RS rating of 70 or moreOutperformed at least 70% of NSE stocks over the past year.80Pass
14Promoter holding not reduced last quarterOwners cutting their stake can be a sign they see less value ahead.+0.00 pts to 34.8%Pass
15FII + mutual fund holding up last quarterLarge investors adding shares is a sign of institutional interest.+0.66 pts to 26.4%Pass
16Delivery % (60 days) above the market medianMore shares taken into demat accounts means more investors, fewer day traders.41% vs 48%Fail
17Not under ASM / GSM surveillanceNSE puts stocks with unusual price or volume moves under extra margin and trading rules.not listedPass
18Not in the F&O ban listIn a ban, open interest is near the market-wide limit and only position-reducing trades are allowed.not an F&O stockn/a

Piramal Pharma vs the Pharma & healthcare sector

Against the 116 scored stocks in Pharma & healthcare. All Pharma & healthcare stocks →

Scores vs sector median

ScorePiramal PharmaSector median
Quality2254
Valuationn/a46
Momentum8966

Top 5 in Pharma & healthcare by quality score

StockQualityValuationMomentumChecks
GLAXO96395914/16
SANOFICONR96492312/16
Procter & Gamble Health92555212/15
Thyrocare Technologies89375511/16
CAPLIPOINT86653511/16

Questions

What is Piramal Pharma’s quality score?
Piramal Pharma’s quality score is 22 out of 100 (Weak) on 18 Nov 2026, from 6 of 6 components: Return on equity (ROE) -2.6% (percentile 4); Return on capital employed (ROCE) 2.3% (percentile 6); Debt / equity 0.70 (percentile 15); Interest cover 0.9× (percentile 5); Profit growth consistency 4 of 8 quarters (percentile 28); Free cash flow margin FY26 8.6% (percentile 72). It is a rank against 1,356 scored NSE stocks, not an absolute grade.
Is Piramal Pharma expensive?
Piramal Pharma made a loss over the last four quarters, so a P/E cannot be worked out and its valuation score is n/a. Its price-to-book ratio is 3.90, against a sector median of 4.44.
How many checklist points does Piramal Pharma pass?
Piramal Pharma passes 9 of 15 applicable checks on 18 Nov 2026 (3 do not apply or lack data). Passed: profit up on a year ago (latest quarter), sales up on a year ago (latest quarter), positive free cash flow (latest full year), price above its 200-day average, price above its 50-day average, RS rating of 70 or more and more. Failed: profit up year on year in at least 6 of the last 8 quarters, return on equity (ROE) of 15% or more, return on capital employed (ROCE) of 15% or more, debt below half of equity (D/E under 0.5), interest cover of 3× or more, delivery % (60 days) above the market median.
How are these scores calculated?
Each score is the average percentile rank of its components among all scored NSE stocks. Quality uses ROE, ROCE, debt/equity, interest cover, how many of the last 8 quarters grew profit year on year, and free cash flow margin (banks, NBFCs and insurers: ROE and profit consistency). Valuation uses P/E against the sector median and against the stock’s own 5-year median, P/B against the sector, and free cash flow yield, with cheaper ranking higher. Momentum uses the RS rating, distance from the 200-day and 50-day averages, place in the 52-week range and 6-month return against NIFTY 50. Scores are relative and change every trading day.

For information and education only; this is not investment advice. ChartMine is not a SEBI-registered investment adviser or research analyst. Scores are relative ranks among NSE stocks and change daily as prices and filings change. Data: NSE daily price files, company results, balance sheets and shareholding filings; a few filings arrive late or contain errors.

See it live on your chart.ChartMine for TradingView.